|
|
Acute
Illness
Protocols |
|
Metabolic
Consultation |
 |
Feedback |
|
Discussion
Forum |
 |
Poll |
--Please
review the contents of these protocols and submit your comments to
be considered for the final online publication--
INTRODUCTION
Maple
syrup urine disease (MSUD) is an organic acid disorder* but is often
classified as an amino acid disorder because of increased levels of
branched chain amino acids as well as the organic acids. The central
emergency features of MSUD are profound metabolic ketoacidosis and
brain edema with lethargy progressing to coma.
*Organic acids are distinguished from amino acids in that they
do not contain nitrogen.
PATHOPHYSIOLOGY
Patients
with MSUD are unable to metabolize the branched chain ketoacids. As
a consequence, they have increased ketoacids and the precursor branched
chain amino acids (leucine, isoleucine and valine). The toxic metabolic
components are leucine and the ketoacids. When excessive
protein is ingested or, more frequently, when the infant/child is
under metabolic stress from an acute illness (febrile upper respiratory
infection, gastroenteritis, etc.) or in the immediate neonatal period,
the increased metabolic rate requires many more calories than the
child is ingesting, the cells begin to break down protein to supply
the needed calories (catabolism). In MSUD, this results in marked
increases in the branched chain amino acids and corresponding ketoacids,
resulting in metabolic ketoacidosis and leucine toxicity. The leucine
further increases because its high level (and the high levels of isoleucine
and valine) block transport of other amino acids into the cells, thus
depleting cells of amino acids required for incorporation of leucine
back into protein. Brain edema is probably a result of high levels
of osmotically active amino acids entrapped in brain cells by the
high leucine levels producing increased intracellular osmolarity plus
low extracellular sodium levels, both acting together to cause movement
of water into the cells.
PRESENTATION
Well at birth but, symptoms may develop quite rapidly
within 4 -7 days. Later in childhood similar symptoms develop during
acute illness.
poor suck, disinterest in feeding
lethargy
weight loss
neurological deterioriation with alternating
hypertonia and hypotonia
dystonic "decerebrate-like" extension
of the arms
seizures
coma
pseudotumor cerebri and / or bulging fontanels
occasionally seen
maple syrup/burnt sugar like odor (from urine,
bodily secretions & ear wax)
Presentation varies
depending on the severity of the metabolic defect. The neonatal form
presents in the first week of life with a life-threatening illness.
Survivors of severe neonatal episodes are often neurologically devastated,
when treatment was delayed. The infantile or late-onset form has a
more insidious presentation with failure to thrive, developmental
delay, and perhaps other neurologic features. Intermittent forms of
MSD are also described. All forms can have acute severe life-threatening
decompensatory episodes.
Parents of
children with diagnosed metabolic disorders know the early signs of
decompensation in THEIR children. Listen to them !!!
DIAGNOSIS
ASSESSMENT
- vital signs, cardiovascular stability
- hydration status
- presence of fever; signs of infection
- neurologic status; evidence of increased intracranial pressure
LABS
Blood
o plasma amino acids
o newborn screening (via tandem mass spectrometry or 'Guthrie
testing' - call lab if suspect)
o (arterial) blood gas
o electrolytes, glucose
o CBC, differential WBC count, platelets
o Serum amylase, lipase (pancreatitis can accompany metabolic episodes)
o ammonia (in ice STAT to lab) if diagnosis not certain
o lactate if diagnosis not certain
Urine
o organic acids
o urinalysis for ketones
o DNPH test
- as needed, cultures of blood, urine and throat
Warning: avoid
lumbar puncture unless absolutely necessary - brain edema may be present
and LP could cause herniation)
Neonatal
MSUD may not display marked abnormalities on routine tests and may
not have metabolic acidosis. If hyperammonemia is present it is usually
mild (<130 µmol/L). CBC and blood lactate are usually normal. The
MAIN abnormalities found are in plasma aminoacids and urine
organic acids. The DNPH test (2,4 dinitrophenylhydrazine) detects
elevated 2-oxoacids in the urine and is a useful rapid screening test.
THERAPY
IMMEDIATE TREATMENT
1. Discontinue
natural protein.
2. Provide the large amount of calories needed (120-140 kcal/kg/day).
3. Provide fluids and sodium to treat dehydration, reestablish
normal perfusion and urine output, and avoid hyponatremia.
4. Enteral therapy with special formula that contains all required
amino acids but is free of the branched chain amino acids
5. Identify and treat the infection or other causes of the
metabolic stress.
SPECIFICS OF
TREATMENT
1. IV fluid
therapy
D10/normal saline with 20 meq
KCL at 1 ½ times maintenance for 1-2 hours.
2. Stat laboratory
tests
As described above
3. Branched
chain amino acid-free formula
This medical product special formula can be made
up by the pharmacy. The pharmacy must be supplied with the exact recipe.
An example is Ketonex 2 (Ross).
This medical product formula provides 30 grams of protein equivalents
and 410 calories per 100 grams of powder. It should be made up as
a 20-25 kcal/oz solution. For an infant, the Ketonex 2 should provide
3-4 grams protein/kg/day. For a child, it should provide 2-3 grams
protein/kg/day.
Ex: For 14 kg child, 120 grams
Ketonex 2 powder in water to 22 oz.
provides 2.6 grams protein/kg and 35 kcal/kg.
There are a number
of other medical product formulas (see below) The only major differences
are the amount of protein equivalents and calories per 100 grams of
powder. For instance, Ketonex-1 has only 15 grams protein equivalents
but 480 calories per 100 grams powder. Certain of these medical product
formulas is appropriate only for infants and others for both children
and adults. The table below lists the pertinent information about
each of the products.
| Product |
Supplier |
Designation |
Nutrition
Prot
Eq (g)
|
Energy
(Kcal) |
| Ketonex
1 |
Ross
|
Infant |
15 |
480 |
| MSUD
1 |
Milupa* |
Infant |
41 |
280 |
| MSUD
Analog |
SHS |
Infant |
13 |
475 |
| Ketonex
2 |
Ross |
Child/Adult |
30 |
410 |
| BCAD-2 |
Mead
Johnson |
Child/Adult |
24 |
410 |
| MSUD
2 |
Milupa*
|
Child/Adult |
54 |
300 |
| MSUD
Maxamaid |
SHS
|
Child |
25 |
309 |
| MSUD
Maxamum |
SHS
|
Adult
|
39 |
297 |
Complex
MSUD
Drink Mix
|
Applied
Nutrition |
Child/Adult |
25 |
410 |
Complex
MSUD
Amino Acid Blood |
Applied
Nutrition |
Child/Adult |
77 |
323 |
Complex
MSUD
Amino Acid Blood |
Applied
Nutrition |
Child/Adult |
21 |
575 |
| |
|
|
|
|
*Distributed in
the U.S. by Mead Johnson
L-alanine and
L-glutamine, each at 250 mg/kg/day, should be added to the medical
product. Both of these amino acids are reduced during acute ketoacidotic
episodes of MSUD.
If one of the special formulas is unavailable, BUT ONLY IF ONE
OF THEM IS UNAVAILABLE, pedialyte orally or Pro-Phree in water
can be given to provide calories as a temporary measure until the
child can be transferred to a metabolic center or the special medical
product formula obtained. The standard recipe for Pro-Phree is to
add 125 grams Pro-Phree to water for total volume of 960 ml, providing
a 20 kcal/oz solution.
If the infant/child does not feed, pass NG or J tube for feeding.
If enteral feeding is not tolerated, can provide the amino acids IV
with the special MSD-TPN amino acid mixture available through PharmaThera
in Memphis, TN (Tel: 800-767-6714). It will be supplied within 24-48
hours as a 5 liter solution. The MSD-TPN is added to the IV fluids
to supply 1.5-2.0 grams protein/100 ml.
4. Calories
Achieve a caloric intake of 120-140 kcal/kg/day with combination
of enteral formula and IV glucose and Intralipid. Approximately 40-50%
of the calories should be as Intralipid and formula.
5. Evaluate the lab results, intake and clinical status. Aims
are:
a. Provide 120-140 kcal/kg/day and
sufficient protein as amino acids free of the branched chain amino
acids
b. Eliminate ketoacidosis as determined
by
- serum bicarbonate level
of 24 meq/L
- absence of ketones in
urine
- negative urine DNPH test
c. Maintain serum sodium at 140-145
meq/L. Monitor urine sodium output to establish loss and replacement
requirement
d. Measure plasma amino acids q12h.
Levels should be reduced to:
- leucine < 300 umol/L
- isoleucine 300 umol/L
- valine 400 umol/L
It is important to realize that isoleucine
and valine levels may drop rapidly and that very low levels (isoleucine
< 100 umol/L and valine < 200 umol/L) will keep the leucine
level from dropping by limiting protein synthesis. Low levels will
also allow more leucine to enter brain by providing less transport
competition and thus will produce or enhance brain edema and neurological
complications. Add isoleucine and valine at 100-150 mg/kg/day to maintain
these levels.
e. Less irritability, increased alertness,
no vomiting, reduced hyperreflexia
6. As serum
sodium approaches 140-145 meq/L, reduce IV fluids to D10/.45 normal
saline and monitor serum sodium closely (hyponatremia enhances brain
edema in MSUD). After 24 hours, adjust sodium intake to provide 4
meq/kg/day. Too much sodium will complicate fluid management.
7. If serum
bicarbonate is below 14 meq/L and blood pH < 7.2, give IV bolus
NaHCO3 as 2.5 meq/kg over 30 minutes, then 2.5 meq/kg/day until serum
bicarbonate is 24-28 meq/L.
8. If blood
glucose rises > 200 mg/dL after one hour of IV infusion, begin
insulin infusion at 0.05-0.1 unit/kg/hr until blood glucose is controlled.
9. If neurological
signs worsen (vomiting, lethargy, hyperreflexia, clonus), suspect
severe cerebral edema. Critical edema most often occurs during
IV therapy, either due to serum sodium below 135 meq/L or continued
ketosis and vomiting. Brain edema with brain stem herniation is the
most frequent cause of death in MSUD. If suspected, obtain brain CT
or MRI. If severe edema confirmed, infuse mannitol at 1- 2 grams/kg
over 30-40 minutes. Add lasix for diuresis but carefully monitor serum
sodium to maintain concentration in the 140-145 meq/L range. Can infuse
hypertonic saline to maintain the level.
10. Vomiting
is the nemesis of MSUD. It provokes a ketoacidotic episode and complicates
enteral therapy. Zofran at 2-4 mg every 6-8 hours can be effective
in controlling vomiting.
11. Hemodialysis
should be a last resort but may be lifesaving in a neonate who presents
with coma and seizures and in whom IV therapy may not correct the
profound metabolic derangements in time to prevent death from cerebral
edema with brain stem compression. This could also be true for an
older infant or child (or even adult). The Renal Service should be
alerted as soon as hemodialysis is considered, well before the decision
to hemodialyze is made, so that adequate preparations can be made
in advance.
RECOVERY
Once the patient
is stable and accepting enteral feeding, the plasma amino acids must
be monitored daily to reestablish amino acid homeostasis. On
the basis of these levels, the branched chain amino acid-free medical
formula with added source of branched chain amino acids and the low
protein foods are adjusted to aim for plasma levels as follows:
leucine 175 umol/L
isoleucine 200 umol/L
valine 300 umol/L
Other amino acids WNL
This will require
careful attention to the amount of medical formula ingested, the amount
of protein added to the formula, the amount of low protein foods ingested
and the amount of supplemental isoleucine and valine added to the
formula (each supplement should be available in the pharmacy as a
100 mg/10 ml solution)
In conjunction
with this protocol, please call or have paged the genetics metabolism
fellow on call, or failing this, the metabolic attending on call at
your hospital or nearest pediatric tertiary care center
Last
Updated: Wednesday, September 6, 2006
|